Quantitative assay for bradykinin in rat plasma by liquid chromatography coupled to tandem mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 54, Issue 3, 2011, Pages 557-561

  Baralla, Elena ^a   Nieddu, Maria ^a   Boatto, Gianpiero ^a   Varoni, Maria Vittoria ^a   Palomba, Domenico ^a   Demontis, Maria Piera ^a   Pasciu, Valeria ^a   Anania, Vittorio ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

Bradykinin; Kallikrein; LC MS MS; Rat plasma; SPE

Indexed keywords

APROTININ; BRADYKININ; BRADYKININ DERIVATIVE; KALLIKREIN; PROTEINASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; LIQUID CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; RAT; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

ANIMALS; APROTININ; BRADYKININ; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; KALLIKREINS; MASS SPECTROMETRY; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; SERINE PROTEINASE INHIBITORS; SOLID PHASE EXTRACTION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; VASODILATOR AGENTS;

EID: 78149500669     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.09.041     Document Type: Article

References (20)

1. Madeddu P., Varoni M.V., Demontis M.P., Chao J., Simson J.A., Glorioso N., Anania V. Kallikrein-kinin system and blood pressure sensitivity to salt. Hypertension 1997, 29:471-477.
2. Pravanec M., Cren V., Cunes J., Scicli A.G., Carretero O.A., Simonet L. Cosegregation of blood pressure with a kallikrein gene family polymorphism. Hypertension 1991, 17:242-246.
3. Majima M., Mizogami S., Kuribayashi Y., Katori M., Oh-ishi S. Hypertension induced by a nonpressor dose of angiotensin II in kininogen-deficient rats. Hypertension 1994, 24:111-119.
4. Wang J., Xiong W., Yang Z., Davis T., Dewey M.J., Chao J. Human tissue kallikrein induces hypotension in transgenic mice. Hypertension 1994, 23:236-243.
5. Song Q., Chao J., Chao L. High level of circulating human tissue kallikrein induces hypotension in a transgenic mouse model. Clin. Exp. Hypertens. 1996, 18:975-993.
6. Varoni M.V., Palomba D., Satta M., Satta A., Anania V. Different response of intracerebroventricular cadmium administration on blood pressure in normal and low urinary kallikrein rats. Pharmacol. Res. 2003, 47:157-162.
7. Madeddu P., Vio C.P., Straino S., Salis M.B., Milia A.F., Emanueli C. Renal phenotype of low kallikrein rats. Kidney Int. 2001, 59:2233-2242.
8. Varoni M.V., Palomba D., Macciotta N.P., Antuofermo E., Deiana G., Baralla E., Anania V., Demontis M.P. Brain renin-angiotensin system modifies the blood pressure response to intracerebroventricular cadmium in rats. Drug Chem. Toxicol. 2010, 33:302-309.
9. Hilgenfeldt U., Linke R., Riester U., Konig W., Breipohl G. Strategy of measuring bradykinin and kallidin and their concentration in plasma and urine. Anal. Biochem. 1995, 228:35-41.
10. Nussberger J., Cugno M., Amstutz C., Cicardi M., Pellacani A., Agostani A. Plasma bradykinin in angio-oedema. Lancet 1998, 351:1693-1697.
11. Campbell D.J. Towards understanding the kallikrein-kinin system: insights from measurement of kinin peptides. Braz. J. Med. Biol. Res. 2000, 33:665-677.
12. van den Broek I., Sparidans R.W., Schellens J.H., Beijnen J.H. Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. J. Chromatogr. B 2008, 872:1-22.
13. Pellacani A., Brunner H.R., Nussberger J. Antagonizing and measurement: approaches to understanding of hemodynamic effects of kinins. J. Cardiovasc. Pharmacol. 1992, 20:S28-34.
14. Wilson S.R., Boix F., Holm A., Molander P., Lundanes E., Greibrokk T. Determination of bradykinin and arg-bradykinin in rat muscle tissue by microdialysis and capillary column-switching liquid chromatography with mass spectrometric detection. J. Sep. Sci. 2005, 28:1751-1758.
15. Murphey L.J., Hachey D.L., Vaughan D.E., Brown N.J., Morrow J.D. Quantification of BK1-5, the stable bradykinin plasma metabolite in humans, by a highly accurate liquid-chromatographic tandem mass spectrometric assay. Anal. Biochem. 2001, 292:87-93.
16. van den Broek I., Sparidans R.W., Schellens J.H., Beijnen J.H. Quantitative assay for six potential breast cancer biomarker peptides in human serum by liquid chromatography coupled to tandem mass spectrometry. J. Chromatogr. B 2010, 878:590-602.
17. Yi J., Kim C., Gelfand C.A. Inhibition of intrinsic proteolytic activities moderates preanalytical variability and instability of human plasma. J. Proteome Res. 2007, 6:1768-1781.
18. Madeddu P., Varoni M.V., Demontis M.P., Pinna Parpaglia P., Glorioso N., Anania V. Urinary kallikrein: a marker of blood pressure sensitivity to salt. Kidney Int. 1996, 49:1422-1427.
19. Amundsen E., Putter J., Friberger P., Knos M., Larsbraten M., Claeson G. Methods for the determination of glandular kallikrein by means of a cromogenic tripeptide substrate. Adv. Exp. Med. 1979, 102A:83-95.
20. Guidance for industry Bioanalytical Method Validation 2001, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CEDR), Center for Veterinary Medicine (CVM), BP. http://www.fda.gov/cder/guidance/4252fnl.htm.